Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)Jürgen Becker, Selma Ugurel, Dirk Schadendorf et al.|EJC Skin Cancer|2025Cited by 0